|1.||Ypsilantis, Petros: 5 articles (03/2009 - 11/2003)|
|2.||Simopoulos, Constantinos: 5 articles (03/2009 - 11/2003)|
|3.||Tentes, Ioannis: 4 articles (03/2009 - 09/2004)|
|4.||Kortsaris, Alexandros: 4 articles (03/2009 - 09/2004)|
|5.||Gedik, Nursal: 4 articles (06/2006 - 09/2004)|
|6.||Denaro, Vincenzo: 3 articles (06/2010 - 01/2008)|
|7.||Di Martino, Alberto: 3 articles (06/2010 - 01/2008)|
|8.||Spence, J David: 3 articles (01/2009 - 08/2007)|
|9.||Urquhart, Bradley L: 3 articles (01/2009 - 08/2007)|
|10.||House, Andrew A: 3 articles (01/2009 - 08/2007)|
06/01/1999 - "Mesna offers good protection against CP cystitis for only certain posologies. "
11/01/1991 - "Although previous reports had suggested that the sulfhydryl-containing compound mesna might be superior to forced diuresis in preventing hemorrhagic cystitis, there were concerns about the effect of mesna on engraftment in these studies. "
11/01/2015 - "Continuous IV infusion of MESNA can prevent hemorrhagic cystitis in HSCT and retain MESNA concentration in urine."
09/01/2015 - "We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p = 0.08]. "
09/01/2015 - "All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. "
04/30/2003 - "In this study, we have confirmed that mesna treatment did not show any curative or preventive effects on either OTA-induced kidney damage or renal tumor development in two different strains that have distinct metabolic characteristics."
04/30/2003 - "However, there was no evidence of any effect of mesna on the incidence and distribution of any type of tumor or non-neoplastic finding in the kidney in either strain or treated group. "
04/30/2003 - "In order to elucidate whether mesna has curative or preventive effects on OTA-induced renal damage or renal tumor development, we administered OTA and/or mesna to both DA and Lewis rats for their life-time and examined kidney, urethra and urinary bladder histologically. "
09/01/1984 - "[Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). "
01/01/1980 - "The untoward urotoxic side effects can be avoided with mesna without interfering with the chemotherapeutic effect on the tumor."
03/01/1993 - "Mesna was very effective in preventing the development of hematuria."
06/01/1986 - "A significant reduction in the incidence of hematuria was observed in the patients receiving mesna. "
04/01/1990 - "The first four patients on the standard-dose study did not receive mesna because it was unavailable; three developed gross hematuria. "
01/01/2007 - "Despite the clinical use of mesna to prevent HC, a significant percent ( approximately 33%) of patients present with at last one feature of HC, mainly hematuria. "
12/01/1997 - "The combination of mesna and HBO, which act through independent mechanisms, resulted in complete protection, since mean histological scores and hematuria levels in this group were not different from controls (p >0.05). "
|4.||Sarcoma (Soft Tissue Sarcoma)
01/01/1996 - "IF/Mesna chemotherapy at this dose and schedule was not found to be very promising in refractory sarcomas as a second-line chemotherapy."
12/01/2003 - "We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma. "
01/01/1997 - "The Gynecologic Oncology Group (GOG) in the United States has recognized the efficacy of ifosfamide and mesna in the treatment of patients with advanced or recurrent uterine sarcomas. "
01/01/2000 - "In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was evaluated in patients with advanced soft tissue sarcomas. "
02/01/1990 - "In a phase II trial of ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection in 124 patients who had previously failed treatment for sarcomas, 3% achieved a complete response (CR), and 18% had a CR or partial response (PR). "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/01/1992 - "The purpose of this study was to evaluate the toxicity and response efficacy of fixed-dose oral ifosfamide (OI)-mesna (M) in advanced, non-small-cell lung cancer (NSCLC). "
02/01/1989 - "20 patients with advanced non-small cell lung cancer were treated with ifosfamide and mesna 1.5 g/m2 daily for 5 days; 10 received the drug by mouth and 10 i.v. Both schedules resulted in a reduction in the elimination half-life with an increased total and nonrenal clearance of ifosfamide over the 5-day period. "
06/01/1988 - "Phase II study of high dose ifosfamide plus mesna in inoperable non small cell lung carcinoma."
11/01/1992 - "Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer."
06/01/1986 - "High-dose ifosfamide (one or two courses of 6 g/m2) with or without mesna was administered to 13 patients with advanced non-small cell lung cancer. "
|5.||Etoposide (VP 16)
|9.||Mesna (Coenzyme M)
|1.||Drug Therapy (Chemotherapy)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)